Skip to main content

Advertisement

Table 2 Age specific attribution of precancerous cervical lesions to vaccine HPV genotypes attending three estimate methods

From: Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain

   CIN2 CIN3-CIS CIN2–3
Method Women age (years) HPV 16/18 (%) HPV 31/33/45/52/58 (%) p HPV 16/18 (%) HPV 31/33/45/52/58 (%) p HPV 16/18 (%) HPV 31/33/45/52/58 (%) p
Minimum estimate 18–34 64 25   71 14 * 69 17 *
35–44 52 39   68 13   62 22 *
≥45 33 33   52 24   45 27 *
p-trend        *   
Proportional attribution 18–34 53 29 * 74 13 * 66 19 *
35–44 48 41 * 64 16 * 59 24 *
≥45 48 26   44 28 * 46 27 *
p-trend        * *  
Hierarchical attribution 18–34 63 23 * 78 12 * 72 16 *
35–44 51 40 * 66 19 * 62 26 *
≥45 50 25   45 32 * 47 29 *
p-trend        * *  
  1. *p-trend < 0.05 for each HPV group prevalence decrease with increasing age
  2. *p < 0.05 for absolute additional fraction of cervical lesions attributable to HPV genotypes targeted by nonavalent vaccine compared to the fraction attributable to those targeted by bi/quadrivalent vaccines